Sequential Bilateral Neurostimulation Aids Treatment-Resistant Depression
By Lori Solomon HealthDay Reporter
WEDNESDAY, Jan. 3, 2024 -- A novel sequential bilateral neurostimulation protocol has the potential to improve treatment-resistant major depressive disorder (TR-MDD), according to a letter published in the November issue of Brain Stimulation.
Sabrina K. Segal, Ph.D., from the Family Care Center in Lone Tree, Colorado, and colleagues conducted a naturalistic retrospective study to examine whether a novel sequential bilateral protocol utilizing high-frequency repetitive transcranial magnetic stimulation (rTMS) to the left dorsolateral prefrontal cortex, followed by intermittent theta burst stimulation to the right dorsolateral prefrontal cortex, is effective for patients with TR-MDD. The analysis included 38 patients with TR-MDD who completed 28 TMS sessions.
The researchers found that mean Patient Health Questionnaire-9 (PHQ-9) scores significantly decreased from 18.18 at timepoint 1 to 10.29 at timepoint 2 and 8.05 at timepoint 3. The response rate was 66 percent, and the remission rate was 24 percent. There were no significant differences between mean PHQ-9 scores at the end of treatment by the coil used (B-70 or B-65). Most patients (84.2 percent) had more than a 5-point score reduction, and two-thirds (68.4 percent) had a final PHQ-9 score <10, showing marked clinical improvement.
"The current results provide a rationale to expand treatment approaches for rTMS beyond the contemporary 'left-excitatory/right-inhibitory' hemispheric lateralization strategy," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Perinatal Suicide Tied to Intimate Partner Problems, Depression, Substance Use
WEDNESDAY, July 3, 2024 -- Perinatal suicide is often associated with intimate partner problems (IPPs) and behavioral health issues, according to a study published online...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.